These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 11870257)

  • 1. Adverse events after imatinib mesylate therapy.
    Elliott MA; Mesa RA; Tefferi A
    N Engl J Med; 2002 Feb; 346(9):712-3. PubMed ID: 11870257
    [No Abstract]   [Full Text] [Related]  

  • 2. Reversible drug-induced interstitial pneumonitis following imatinib mesylate therapy.
    Rajda J; Phatak PD
    Am J Hematol; 2005 May; 79(1):80-1. PubMed ID: 15849772
    [No Abstract]   [Full Text] [Related]  

  • 3. Hypersensitivity pneumonitis related to imatinib mesylate.
    Bergeron A; Bergot E; Vilela G; Ades L; Devergie A; Espérou H; Socié G; Calvo F; Gluckman E; Ribaud P; Rousselot P; Tazi A
    J Clin Oncol; 2002 Oct; 20(20):4271-2. PubMed ID: 12377975
    [No Abstract]   [Full Text] [Related]  

  • 4. Uncommon syndromes and treatment manifestations of malignancy: Case 4. Periorbital edema and imatinib mesylate therapy for chronic myelogenous leukemia.
    Ramar K; Potti A; Mehdi SA
    J Clin Oncol; 2003 Jan; 21(1):172-3. PubMed ID: 12506189
    [No Abstract]   [Full Text] [Related]  

  • 5. Prominent pleural effusion possibly due to imatinib mesylate in adult Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Ishii Y; Shoji N; Kimura Y; Ohyashiki K
    Intern Med; 2006; 45(5):339-40. PubMed ID: 16596010
    [No Abstract]   [Full Text] [Related]  

  • 6. Unusual extramedullary relapses under imatinib mesylate treatment in chronic myeloid leukemia.
    Beyazit Y; Aksu S; Kekilli M; Haznedaroglu IC; Kilickap S; Goker H
    Am J Hematol; 2005 May; 79(1):79-80. PubMed ID: 15849758
    [No Abstract]   [Full Text] [Related]  

  • 7. Histological features of acute hepatitis after imatinib mesylate treatment.
    James C; Trouette H; Marit G; Cony-Makhoul P; Mahon FX
    Leukemia; 2003 May; 17(5):978-9. PubMed ID: 12750713
    [No Abstract]   [Full Text] [Related]  

  • 8. Trachyonychia in a patient with chronic myeloid leukaemia after imatinib mesylate.
    Lau YM; Lam YK; Leung KH; Lin SY
    Hong Kong Med J; 2014 Oct; 20(5):464.e2. PubMed ID: 25307080
    [No Abstract]   [Full Text] [Related]  

  • 9. Successful progressive challenge after a cutaneous reaction to imatinib mesylate (Gleevec): a case report and review of the literature.
    Park MA; Volcheck GW; Guarderas JC
    Allergy Asthma Proc; 2004; 25(5):345-7. PubMed ID: 15603208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interstitial pneumonitis during imatinib therapy.
    Isshiki I; Yamaguchi K; Okamoto S
    Br J Haematol; 2004 May; 125(4):420. PubMed ID: 15142112
    [No Abstract]   [Full Text] [Related]  

  • 11. Lack of imatinib-induced thyroid dysfunction in a cohort of non-thyroidectomized patients.
    Dora JM; Leie MA; Netto B; Fogliatto LM; Silla L; Torres F; Maia AL
    Eur J Endocrinol; 2008 May; 158(5):771-2. PubMed ID: 18426838
    [No Abstract]   [Full Text] [Related]  

  • 12. Irreversible imatinib-induced pneumonitis following long-term imatinib administration.
    Seki N; Ito A; Watanabe K; Shibakuki R; Seto T; Uematsu K; Mine T; Eguchi K
    Intern Med; 2007; 46(23):1941-2. PubMed ID: 18057772
    [No Abstract]   [Full Text] [Related]  

  • 13. [A case of lichen planus associated to treatment with imatinib].
    Martínez de Lagrán Z; González-Hermosa MA; Blaya-Alvarez B; Díaz-Pérez JL
    Med Clin (Barc); 2009 Nov; 133(20):805-6. PubMed ID: 19243795
    [No Abstract]   [Full Text] [Related]  

  • 14. Panniculitis in a patient with chronic myelogenous leukaemia treated with imatinib.
    Ugurel S; Lahaye T; Hildenbrand R; Glorer E; Reiter A; Hochhaus A; Schadendorf D; Goerdt S
    Br J Dermatol; 2003 Sep; 149(3):678-9. PubMed ID: 14511021
    [No Abstract]   [Full Text] [Related]  

  • 15. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
    Cortes J; Giles F; O'Brien S; Thomas D; Albitar M; Rios MB; Talpaz M; Garcia-Manero G; Faderl S; Letvak L; Salvado A; Kantarjian H
    Cancer; 2003 Jun; 97(11):2760-6. PubMed ID: 12767088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac tamponade associated with imatinib mesylate therapy of chronic myelogenous leukemia.
    Barton JC; Jones SC; Lamberth WC; Reymann MT; Scott VC
    Am J Hematol; 2002 Oct; 71(2):139-40. PubMed ID: 12353320
    [No Abstract]   [Full Text] [Related]  

  • 17. Imatinib mesylate-induced pseudoporphyria in two children.
    Mahon C; Purvis D; Laughton S; Bradbeer P; Teague L
    Pediatr Dermatol; 2014; 31(5):603-7. PubMed ID: 24920470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib mesylate-induced acute hepatitis with autoimmune features.
    Dhalluin-Venier V; Besson C; Dimet S; Thirot-Bibault A; Tchernia G; Buffet C
    Eur J Gastroenterol Hepatol; 2006 Nov; 18(11):1235-7. PubMed ID: 17033447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib mesylate-induced acute hepatitis in a patient treated for gastrointestinal stromal tumour.
    Pariente A; Etcharry F; Cales V; Laborde Y; Ferrari S; Biour M
    Eur J Gastroenterol Hepatol; 2006 Jul; 18(7):785-7. PubMed ID: 16772838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor lysis syndrome after STI571 in Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Dann EJ; Fineman R; Rowe JM
    J Clin Oncol; 2002 Jan; 20(1):354-5. PubMed ID: 11773197
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.